Lakeside Signs $1.5 Million Sales Agreement with Sinopharm Group Subsidiary

Rhea-AI Summary

Lakeside Holding (Nasdaq: LSH) has announced that its subsidiary Hupan Pharmaceutical signed a $1.5 million sales agreement with Sinopharm Holding Hubei New Special Medicine, a subsidiary of Sinopharm Group. The agreement, effective from January 1, 2025, through year-end, covers the delivery of critical medicines including Sodium Bicarbonate, Glucose, and Glucose Sodium Chloride.

This agreement follows a previous partnership with Sinopharm Group focused on medicine storage, transportation, and logistics services, strengthening Hupan Pharmaceutical's position as a pharmaceutical solutions provider in China.

Positive

• Secured new $1.5 million sales agreement for 2025
• Expanded business relationship with major healthcare player Sinopharm Group
• Builds upon existing logistics partnership announced previous month

Negative

• None.

Insights

Financial Analyst

The $1.5 million sales agreement with Sinopharm's subsidiary represents a significant development for Lakeside, given their $19.2 million market cap. This contract value accounts for approximately 7.8% of their market capitalization, making it a material revenue contributor. The deal's strategic importance extends beyond its monetary value, as it strengthens Lakeside's foothold in China's pharmaceutical distribution network through partnership with one of the country's largest healthcare companies. The one-year term provides clear revenue visibility for 2025, while the focus on essential medicines like Sodium Bicarbonate and Glucose suggests stable, recurring demand patterns. This follows their recent logistics partnership with Sinopharm Group, indicating successful execution of their expansion strategy in the Chinese healthcare market.

Supply Chain Analyst

This agreement marks a strategic expansion of Lakeside's cross-border supply chain operations in the Asia-Pacific region. The deal encompasses critical medical supplies that require specialized handling and consistent delivery schedules, demonstrating Lakeside's growing capabilities in pharmaceutical logistics. The partnership with Sinopharm Hubei, following their previous logistics services agreement, creates potential synergies in their supply chain operations. This vertical integration - combining product supply with logistics services - could lead to improved operational efficiency and stronger competitive positioning. The focus on essential medicines also suggests lower supply chain volatility and more predictable inventory management cycles.

Agreement to Deliver Critical Medicines 

ITASCA, Ill., Dec. 17, 2024 /PRNewswire/ -- Lakeside Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a U.S.-based cross-border supply chain solution provider with a unique focus on the Asia-Pacific market is pleased to announce that Hupan Pharmaceutical has signed a Sales Agreement (the "Agreement") with Sinopharm Holding Hubei New Special Medicine Co., Ltd. ("Sinopharm Hubei"), a subsidiary of Sinopharm Group. The Agreement, valued at approximately RMB 11.0 million (approximately $1.5 million), is effective from January 1, 2025, through the end of the year and involves the sale and delivery of critical medicines, including Sodium Bicarbonate, Glucose, and Glucose Sodium Chloride. 

This Agreement follows the partnership with Sinopharm Group announced last month focusing on essential medicine storage, transportation, and logistics services. These achievements reflect Hupan Pharmaceutical's expanding role as a reliable provider of pharmaceutical solutions in China.

"We are excited to strengthen our relationship with Sinopharm Group further, a leading global player in the healthcare industry," said Lan Su, COO of Lakeside Holding Limited. "This Agreement demonstrates our capabilities in delivering high-quality pharmaceutical products, ensuring reliable supplies of essential medicines. We remain committed to broadening our portfolio and expanding our market reach, enhancing our role as a trusted pharmaceutical solutions provider."

About Lakeside Holding Limited

Lakeside Holding Limited is a U.S.-based cross-border supply chain solution provider with a unique focus on the Asia-Pacific market. Through two specialized subsidiaries—American Bear Logistics and Hupan Pharmaceutical (Hubei) Co., Ltd.—Lakeside delivers tailored logistics solutions spanning general and specialized sectors.

American Bear Logistics, with strategic hubs in Chicago, Dallas, Los Angeles, and New York, offers customized cross-border ocean and airfreight solutions, connecting Asia-based logistics service companies and e-commerce platforms with the U.S. market.

Lakeside recently acquired Hupan Pharmaceutical (Hubei) Co., Ltd., expanding its service scope and enhancing its pharmaceutical logistics and distribution capabilities within China. This strategic move underscores Lakeside's commitment to advancing integrated cross-border logistics solutions.

For more information, please visit https://lakeside-holding.com.    

Safe Harbor Statement

This press release contains forward-looking statements that reflect our current expectations and views of future events. Known and unknown risks, uncertainties and other factors, including those listed under "Risk Factors," may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. You can identify some of these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements involve various risks and uncertainties. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. We qualify all of our forward-looking statements by these cautionary statements.

Investor Relations Contact:
Matthew Abenante, IRC
President
Strategic Investor Relations, LLC
Tel: 347-947-2093
Email: matthew@strategic-ir.com

View original content:https://www.prnewswire.com/news-releases/lakeside-signs-1-5-million-sales-agreement-with-sinopharm-group-subsidiary-302333394.html

SOURCE Lakeside Holding Limited

FAQ

What is the value of Lakeside's (LSH) new sales agreement with Sinopharm Hubei?

The sales agreement is valued at approximately RMB 11.0 million (approximately $1.5 million).

What products will Lakeside (LSH) supply under the new Sinopharm agreement?

Lakeside will supply critical medicines including Sodium Bicarbonate, Glucose, and Glucose Sodium Chloride.

When does Lakeside's (LSH) new Sinopharm sales agreement take effect?

The agreement is effective from January 1, 2025, through the end of the year.

How does this agreement relate to Lakeside's (LSH) previous partnership with Sinopharm?

This agreement follows a previous partnership focused on essential medicine storage, transportation, and logistics services announced the month before.